Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NervGen Pharma ( (TSE:NGEN) ) has shared an announcement.
NervGen Pharma has reported its 2024 year-end financial results and business updates, highlighting significant progress in the clinical development of its lead drug candidate, NVG-291, for spinal cord injury (SCI). The company completed enrollment in the chronic cohort and began enrollment in the subacute cohort of its Phase 1b/2a clinical trial, with topline data expected in June 2025. Additionally, the FDA has approved an expanded access protocol for NVG-291, and preclinical studies of NVG-300 in ischemic stroke and SCI have shown promising results. The company plans to use proceeds from recent financing to fund ongoing research and development activities through Q3 2025.
More about NervGen Pharma
NervGen Pharma Corp. is a clinical-stage biotech company focused on developing neurorestorative therapeutics. The company is primarily involved in advancing treatments for spinal cord injury and other neurological conditions, with a market focus on innovative drug candidates such as NVG-291 and NVG-300.
YTD Price Performance: -2.16%
Average Trading Volume: 51,478
Technical Sentiment Signal: Strong Sell
Current Market Cap: $149.3M
For an in-depth examination of NGEN stock, go to TipRanks’ Stock Analysis page.